Science

Anven is developing next generation therapeutics and diagnostics that have many of the desirable properties of both monoclonal antibodies (mAbs) and small molecules yet avoid the major disadvantages of each of these mature platforms.  Our new class of small molecules offers unprecedented, targeted protein degradation and durable non-refrigerated handling. Our therapeutic molecules also offer inherent protease resistance and enhanced membrane permeability to enable intestinal absorption, transit of the blood brain barrier, and cell penetration -- i.e., orally administered therapeutics with antibody-like properties.

Leveraging a novel domain of highly specific bio-functional molecules to identify and map previously unobtainable disease-related antigens and antibodies enabling rapid development of new, more effective therapeutics & more specific diagnostics.

Why a new approach is needed?

Many diseases appear to involve unknown molecular variations outside of current libraries and collections, such as:

  - abnormal proteins (e.g. misfolded, aggregates, etc.)

  - disease-related post-translationally modified proteins (PTMs)

  - exogenous agents (bacteria, novel virus, fungus, etc.)

In these situations, current therapeutic development approaches may be incapable to identify and map relevant pathological antigens and antibodies. Consequently, years of effort and billions of dollars are spent — and nearly 90% of clinical trials fail.